Response Genetics, Inc. Announces Contract With MultiPlan, Inc.

Response Genetics, Inc. Announces Contract With MultiPlan, Inc.

LOS ANGELES, Aug. 12, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc.
(Nasdaq:RGDX), a company focused on the development and sale of molecular
diagnostic tests that help determine a patient's response to cancer therapy,
today announced that it has entered into an agreement with MultiPlan, Inc.,
the industry's most comprehensive provider of healthcare cost management
solutions.

As a participating provider in the PHCS and MultiPlan Networks, MultiPlan's
clients will now have access to all of Response Genetics' molecular diagnostic
testing. Response Genetics specializes in predictive genomic testing that
supplies treating physicians with actionable information helping the
physicians determine what drugs will have the greatest response from each of
their patients battling lung, colorectal, gastric and melanoma cancers. The
personalized nature of Response Genetics' testing allows for each patient to
be placed on the most effective drug regimen for his or her cancer treatment.

About MultiPlan

MultiPlan, Inc. is the industry's most comprehensive provider of healthcare
cost management solutions. The company provides a single gateway to a host of
primary, complementary and out-of-network strategies for managing the
financial risks associated with healthcare claims. Clients include
insurers/health plans, third-party administrators, self-funded employers, HMOs
and other entities that pay medical bills in the commercial healthcare,
government, workers compensation and auto markets. MultiPlan contracts with
over 900,000 healthcare providers across the nation and has an estimated 67
million consumers accessing its provider network products. MultiPlan is owned
by BC Partners, a leading international private equity firm, and Silver Lake,
the world's largest private investor in technology. For more information,
visit www.MultiPlan.com.

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical
laboratory focused on the development and sale of molecular diagnostic testing
services for cancer. The Company's technologies enable extraction and analysis
of genetic information derived from tumor cells stored as formalin-fixed and
paraffin-embedded specimens. The Company's principal customers include
oncologists and pathologists. In addition to diagnostic testing services, the
Company generates revenue from the sale of its proprietary analytical
pharmacogenomic testing services of clinical trial specimens to the
pharmaceutical industry. The Company's headquarters is located in Los Angeles,
California.For more information, please visit www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and
the statements of representatives of the Company related thereto contain or
may contain, among other things, certain forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and
uncertainties.Such statements may include, without limitation, statements
with respect to the Company's plans, objectives, projections, expectations and
intentions, such as the ability of the Company, to provide clinical testing
services to the medical community, to continue to strengthen and expand its
sales force, to continue to build its digital pathology initiative, to attract
and retain qualified management, to continue to strengthen marketing
capabilities, to expand the suite of ResponseDX® products, to continue to
provide clinical trial support to pharmaceutical clients, to enter into new
collaborations with pharmaceutical clients, to enter into areas of companion
diagnostics, to continue to execute on its business strategy and operations,
to continue to analyze cancer samples and the potential for using the results
of this research to develop diagnostic tests for cancer, the usefulness of
genetic information to tailor treatment to patients, and other statements
identified by words such as "project," "may," "could," "would," "should,"
"believe," "expect," "anticipate," "estimate," "intend," "plan" or similar
expressions.

These statements are based upon the current beliefs and expectations of the
Company's management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the Securities Exchange
Commission.Actual results, including, without limitation, actual sales
results, if any, or the application of funds, may differ from those set forth
in the forward-looking statements.These forward-looking statements involve
certain risks and uncertainties that are subject to change based on various
factors (many of which are beyond the Company's control).The Company
undertakes no obligation to publicly update forward-looking statements,
whether because of new information, future events or otherwise, except as
required by law.

CONTACT: Investor Relations Contact:
         Peter Rahmer
         Trout Group
         646-378-2973
        
         Company Contact:
         Thomas A. Bologna
         Chairman & Chief Executive Officer
         323-224-3900

Response Genetics Logo
 
Press spacebar to pause and continue. Press esc to stop.